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Genotype-Phenotype Correlation in 153 Adult
Patients With Congenital Adrenal Hyperplasia due to
21-Hydroxylase Deficiency: Analysis of the United
Kingdom Congenital Adrenal Hyperplasia Adult Study
Executive (CaHASE) Cohort
Nils Krone, Ian T. Rose, Debbie S. Willis, James Hodson, Sarah H. Wild,
Emma J. Doherty, Stefanie Hahner, Silvia Parajes, Roland H. Stimson,
Thang S. Han, Paul V. Carroll, Gerry S. Conway, Brian R. Walker,
Fiona MacDonald, Richard J. Ross, and Wiebke Arlt for the United Kingdom
Congenital adrenal Hyperplasia Adult Study Executive (CaHASE)
Context: In congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, a strong gen-
otype-phenotype correlation exists in childhood. However, similar data in adults are lacking.
Objective: The objective of the study was to test whether the severity of disease-causing CYP21A2
mutations influences the treatment and health status in adults with CAH.
Research Design and Methods: We analyzed the genotype in correlation with treatment and
health status in 153 adults with CAH from the United Kingdom Congenital adrenal Hyperplasia
Adult Study Executive cohort.
Results: CYP21A2 mutations were distributed similarly to previously reported case series. In 7
patients a mutation was identified on only 1 allele. Novel mutations were detected on 1.7% of
alleles (5 of 306). Rare mutations were found on 2.3% of alleles (7 of 306). For further analysis,
patients were categorized into CYP21A2mutation groups according to predicted residual enzyme
function: null (n  34), A (n  42), B (n  36), C (n  34), and D (n  7). Daily glucocorticoid dose
was highest in group null and lowest in group C. Fludrocortisone was used more frequently in
patients with more severe genotypes. Except for lower female height in group B, no statistically
significant associations between genotype and clinical parameters were found. Androgens, blood
pressure, lipids, blood glucose, and homeostasis model assessment of insulin resistance were not
different between groups. Subjective health status was similarly impaired across groups.
Conclusions: In adults with classic CAH and women with nonclassic CAH, there was a weak asso-
ciation between genotype and treatment, but health outcomes were not associated with geno-
type. The underrepresentation of males with nonclassic CAH may reflect that milder genotypes
result in a milder condition that is neither diagnosed nor followed up in adulthood. Overall, our
results suggest that the impaired health status of adults with CAH coming to medical attention is
acquired rather thangenetically determinedand therefore couldpotentially be improved through
modification of treatment. (J Clin Endocrinol Metab 98: E346–E354, 2013)
Congenital adrenal hyperplasia (CAH) due to 21-hy-droxylase deficiency (21OHD) is an autosomal re-
cessive disorder and one of the most frequent inborn con-
ditions. Inactivating mutations in the 21-hydroxylase
(CYP21A2) gene account for approximately 95%of cases
(1–3). Steroid 21-hydroxylase deficiency is clinically clas-
sified into classic CAH, comprising the salt-wasting (SW)
and the simple virilizing (SV) forms, and nonclassic CAH.
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Abbreviations: BP, Blood pressure; CAH, congenital adrenal hyperplasia; CaHASE, Con-
genital adrenal Hyperplasia Adult Study Executive; HOMA-IR, homeostasis model assess-
ment of insulin resistance; 21OHD, 21-hydroxylase deficiency; 17OHP, 17-hydroxyproges-
terone; QOL, quality of life; SF-36, 36-item short form health survey; SV, simple virilizing;
SW, salt wasting.
J C E M O N L I N E
A d v a n c e s i n G e n e t i c s — E n d o c r i n e C a r e
E346 jcem.endojournals.org J Clin Endocrinol Metab, February 2013, 98(2):E346–E354
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 26 June 2014. at 06:44 For personal use only. No other uses without permission. . All rights reserved.
The classic form occurs in a frequency of approximately 1
in 10 000 to 1 in 15 000 in the general population,
whereas the nonclassic form is more frequent with an es-
timated incidence of about 1 in 1000 (1). The classic form
of 21-hydroxylase deficiency is characterized by androgen
excess, glucocorticoid deficiency, and, in two thirds of
CAH patients, mineralocorticoid deficiency (1, 2).
In more than 95% of patients with 21OHD, common
CYP21A2 mutations are detected. Approximately 20%–
25% of mutant alleles in 21OHD are CYP21A2 gene de-
letions and CYP21A1P/CYP21A2 chimeric genes (tradi-
tionally termed large gene conversions) caused by unequal
crossing-over events within the RCCX locus (4). The
transfer of genetic material from the CYP21A1P pseudo-
gene into the CYP21A2 gene accounts for about 70%–
75%ofCYP21A2 disease-causing mutations, including 7
point mutations, a deletion of 8 base pairs in exon 3, and
a cluster of 3 point mutations in exon 6 (1, 5). In addition,
more than 100 pseudogene-independent mutations are
listed by the Human Cytochrome P450 allele Nomencla-
ture Committee (http://www.cypalleles.ki.se/cyp21.htm).
CYP21A2 genotypes have been categorized into different
mutation groups based on their in vitro 21-hydroxylase
activity; using these categories, a strong genotype-pheno-
type correlation has been established with high positive
predictive value for salt wasting (5) and impairment of
adrenomedullary function (6) (Figure 1A).
In recent years, increasing attention has been paid to
long-term health problems in adults withCAH (7–9).Our
recent cohort study [United Kingdom Congenital adrenal
Hyperplasia Adult Study Executive (CaHASE)] of 203
adults with congenital adrenal hyperplasia demonstrated
their suboptimal health status with a poor metabolic pro-
file, impaired fertility, and reduced quality of life (QOL)
(10), but the cause for these poor outcomes remains to be
elucidated. We hypothesized that the severity of the dis-
ease-causingCYP21A2mutationmight influence the out-
come andhealth status in adultswithCAH.To this endwe
have carried out a comprehensive genotype-phenotype
analysis in the UK CaHASE cohort.
Patients and Methods
Patients were recruited from 17 centers into this nationwide
study as previously described (10). The study protocol was ap-
proved byWestMidlandsMulticentre Research Ethics Commit-
tee (MREC/03/7/086) and registered with www.ClinicalTrials-
.gov (NCT00749593). All patients were 18 years old or older
and had a confirmed diagnosis of CAH. The recruitment started
August 2004 and ended July 2007. Written informed consent
was obtained from all participants.
General procedures
All participants were seen at the center routinely responsible
for their clinical care in the morning after fasting overnight and
taking their regular medication. After medical history and phys-
ical examination, fasting blood samples were taken. Thereafter
patients were served breakfast and psychometric questionnaires
were completed.Thephysical examination included recordingof
blood pressure (BP) (3 seated and 1 standing, separated by 5
minutes), height, weight, waist circumference, presence and de-
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Figure 1. Definition of mutation groups and their distribution in the
cohort. A, Genotype-phenotype correlations in CAH due to 21-
hydroxylase deficiency based on in vitro CYP21A2 activity. Mutation
groups null and A are associated with the SW form of 21OHD, group B
with the SV form, and group C with the nonclassic (NC) form. E6
cluster refers to the p.Ile236Asn, p.Val237Glu, and p.Met239Leu
mutation cluster at exon 6; intron splice refers to the c.293–13A/CG
mutation (other names: i2G, I2G, IVS2–13A/CG); 8bp refers to the
p.Gly110ValfsX21 mutation. B, Patient cohort according to CYP21A2
mutation group and gender.
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gree of stretch marks, and in females hirsutism and in males
testicular volume (orchidometer) and presence of masses.
The following biochemical parameters were assessed: renal
and liver function, fasting plasma glucose, serum insulin, cho-
lesterol (total, low density lipoprotein, and high-density lipo-
protein), triglycerides, plasma renin activity, and steroid
hormones including 17-hydroxyprogesterone (17OHP), andro-
stenedione, testosterone, and SHBG. The median (interquartile
range) for the time from intake of last glucocorticoid dose until
blood sampling was 3.75 (2.25–12.5) hours. All biochemical
measurements were performed at local laboratories. The results
were recorded as below, within, or above the local reference
range, apart from 17OHP, androstenedione, and plasma renin,
for which absolute values were compared with previously rec-
ommended target ranges for patients with CAH and adrenal
insufficiency (1, 5). All laboratories participate in the United
KingdomNational External Quality Assessment Service scheme
for quality control of steroid immunoassays. Serum insulin was
measured in a single laboratory using an ultrasensitive ELISA
(DRG Instruments, Marburg, Germany) and used for calcula-
tion of homeostasis model assessment of insulin resistance
(HOMA-IR). Psychometric evaluation was carried out using
self-administered questionnaires, including 2 validated ques-
tionnaires for the assessment of subjective health status [36 item
short form health survey (SF-36)].
Mutation analysis, mutation groups, and in vitro
analysis of CYP21A2 mutations
DNA was available for mutation analysis of the CYP21A2
gene in 153 of 203 patients from the UK CaHASE cohort (10).
CYP21A2 gene deletion and chimeric genes were detected using
a commercially available multiplex-ligation probe amplification
strategy following the manufacturer’s protocol (mrc-Holland,
Amsterdam, The Netherlands). Pseudogene-derived CYP21A2
point mutations were detected by targeted multiplex minise-
quencing after allele-specific PCRamplificationof theCYP21A2
gene analysis as described previously (11). Sequence variants
were designated according toHumanGenomeVariation Society
recommendations (www.hgvs.org/rec.html) using the reference
sequencesGenBankNC_000006 (genomicDNA)andGen-Bank
NP_000491.4 (protein).
If themultiplex-ligation probe amplification analysis showed
complex rearrangements, a second published PCR amplification
method (12) was used to avoid nonamplification of the
CYP21A2 gene and misinterpretation of the results, which was
also followed by multiplex minisequencing. If no common mu-
tations were detected, direct DNA sequencing of the entire
CYP21A2 gene was performed (13).
Patients were categorized into established CYP21A2 muta-
tion groups according to their genotype, with the less severe
mutation determining the group: null (mutations predicting ab-
sent in vitro activity), A (intron 2 splice site mutation), B
(mutations such as the p.IIe172Asn mutation and mutations
with 1%–10% in vitro residual enzyme activity), C (mutations
such as p.Pro30Leu, p.Val281Leu, and p.Pro453Ser or
greater than 20%–30% in vitro 21-hydroxylase activity)
(14–16) (Figure 1A).
To allocate patients to appropriate mutation groups, the en-
zymatic activity of novel or rare CYP21A2 missense mutations
without published residual 21-hydroxylase activity was ana-
lyzed using a previously published in vitro expression assaymea-
suring the conversionofprogesterone to11-deoxycorticosterone
in five independent triplicates (17).
Statistical analysis
Patients were stratified according to their genotypes intomu-
tation groups. Continuous variables were analyzed using
ANOVA,withpost hoc comparisonsbetweengroupsbyTukey’s
test. When the assumptions of ANOVA were not met, Kruskal-
Wallis tests were used, with comparisons between groups using
the post hoc pairwise comparisons in SPSS 19 (IBM SPSS Inc,
Chicago, Illinois). Rates were compared using Fisher’s exact
tests.Where significant differences were detected, post hoc com-
parisons between groups were made, with the critical P value
Bonferroni corrected to account for the effect of multiple com-
parisons. These analyses were performed using SPSS version
19.0.0 (IBM SPSS Inc), with P .05 or the corresponding Bon-
ferroni-adjusted P value when multiple comparisons are made,
deemed significant.
Reference data for SF-36 scores were obtained from John
Brazier (University of Sheffield, Sheffield, United Kingdom) in-
cluding a representative random sample of 14 430 subjects aged
between 18 and 79 years from the UK population.We randomly
selected20 (SF-36) sex- andage-matchedcontrols for everyCAH
patient from the respective reference samples for comparison.
Score values from patients and controls were transformed into
age-adjusted (decade) and sex-adjusted z-scores, with subse-
quent comparison by the Mann-Whitney U test. These analyses
were performed using Stata version 10 (College Station, Texas)
and SPSS version 18.0 (SPSS). Statistical significance was as-
sumed when P  .05.
Results
Molecular genetic analysis
CYP21A2mutation analysis was performed in 153 pa-
tients [median age 35 years (range 18–69 years); 103 fe-
males, 50 males]. The distribution of mutations in our
cohort is similar to population studies analyzing the allele
frequency of CYP21A2 mutations in CAH patients from
published cases series (Supplemental Table 1, published
on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org). In 7 patients a mutation
was identified on only 1 allele. Novel mutations were de-
tected on 1.7% of alleles (5 of 306) and rare mutations
were detected on 2.3% of alleles (7 of 306). Mutations
were classified according to their published in vitro activ-
ity; for novel variants and mutations without published
activities activity was measured using in vitro expression
assays (17). The 5 novel mutations included 1 missense
mutation (g.752CT, p.R124C), 1 nonsense mutation
(g.803CT, p.Q141X), 1 splice site mutation (IVS9
1GC), and 2 frame shift mutations (g.2047delG,
p.V334fxX28; g.2674dupC, p.R483PfsX40). The p.R124C
mutation had a residual activity for the conversion of pro-
gesterone todeoxycorticosteroneof16%(0.6SEM)and
was classified as a mutation group B variant. The previ-
E348 Krone et al Genotype-Phenotype Analysis in Adults With CAH J Clin Endocrinol Metab, February 2013, 98(2):E346–E354
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 26 June 2014. at 06:44 For personal use only. No other uses without permission. . All rights reserved.
ously published L308F mutation showed a residual activ-
ity of approximately 3% (3.2% 0.6 SEM) for 21-hy-
droxylation of progesterone and was categorized into
mutation group B, which is in line with a previous pre-
diction that this variant should lead to moderate func-
tional impairment as it was found in a patient with simple
virilizing CAH (18). The previously published variant
p.R435C (19) hada residual activity of approximately 7%
(6.5%  0.9 SEM) for the conversion of progesterone to
deoxycorticosterone.
Patients were categorized into CYP21A2 mutation
groups for further analysis: null 34 (19 females, 15males), A
42 (24 females, 18males), B 36 (25 females, 11males), C 34
(29females,5males),andD7(6females,1male) (Figure1B).
The 7 patients in mutation groupDwere excluded from the
furtherdata analysis because this groupcomprisedheterozy-
gous patients in whom the phenotype prediction is not
possible.
Anthropometric and metabolic data
The age distribution was similar between mutation
groups except for all and female patients in mutation group
B, who were slightly older than patients in mutation group
null (Table 1). Anthropometric measures did not differ be-
tween mutation groups in either sex, with the exception of
women inmutation groupBhaving a lower final height than
females in other genotype groups.
There were no differences between mutation groups in
systolic or diastolic BP (Table 1), blood glucose concen-
trations or HOMA-IR, or lipid profiles (Table 2).
Steroid replacement therapy and quality of
biochemical control
Patients with null genotypes received higher hydrocor-
tisone doses than patients in mutation group C. We also
observed a trend toward higher doses of prednisolone and
dexamethasone in patients with predicted SW-CAH
(groups null and A) than in the patients in groups associ-
atedwithSV-CAH(groupB)ornonclassicCAH(groupC)
(Table 3).
Biochemical disease control did not differ betweenmu-
tation groups. Only 16% of patients with null mutations
(5 of 31), 7%of patientswith groupAmutations (3 of 41),
12% of patients with group B mutations (4 of 34), and
29% of patients with group C mutations (9 of 31) had
17OHP concentrations in the target range (12–36 nmol/
L). All other patients had either suppressed or increased
17OHP concentrations, which did not correlate with the
underlying genotype (Supplemental Figure 1A). Com-
pared with 17OHP, a higher percentage of patients
achieved normal values for androstenedione (3–11 nmol/
L), again with no differences between mutation groups:
19% of females and 42% of males in group null; 44% of
females and 44%ofmales in groupA; 26%of females and
20% of males in group B; and 41% of females in group C
(Supplemental Figure 1, B and C). Most men (85%) in all
mutation groups had normal testosterone concentrations
across CYP21A2 mutation groups. Only half of the
women had normal testosterone concentrations (53%),
with 23.9% having suppressed (24% of null; 14% of A,
44%ofB, and15%ofC)and23%increased (29%ofnull,
23% of A, 17% of B, and 23% of C) testosterone values.
Table 1. Anthropometric Measurements and Blood Pressure
Gender
Mutation Group Significance
of Mutation
Group (ANOVA)Null A B C
Age, ya All 27.98 (25.65–30.52) 32.04 (29.15–35.22) 39.42 (34.95–44.46) 33.79 (30.37–37.60) .001b
Male 26.31 (22.75–30.41) 31.33 (26.31–37.30) 35.70 (28.81–44.24) 28.75 (18.00–45.91) .123
Female 29.37 (26.25–32.87) 32.59 (29.09–36.51) 41.18 (35.37–47.93) 34.74 (31.11–38.81) .003b
Height, cmc All 160.76 (7.11) 159.50 (9.52) 154.49 (9.99) 158.50 (8.03) .021b
Male 166.20 (5.38) 163.72 (9.04) 165.20 (8.59) 161.80 (10.64) .698
Female 156.4 (5.11) 156.33 (8.76) 150.20 (6.84) 157.93 (7.58) .001b
Body mass index, kg/m2a All 28.08 (26.13–30.17) 31.32 (28.99–33.83) 29.73 (27.65–31.96) 30.07 (27.88–32.43) .211
Male 28.43 (24.90–32.46) 29.99 (27.36–32.88) 27.71 (24.30–31.61) 28.64 (24.38–24.90) .760
Female 27.81 (25.48–30.35) 32.25 (28.68–36.50) 30.57 (27.94–33.45) 30.32 (27.79–33.08) .221
Waist circumference, cma All 90.81 (85.96–95.94) 98.65 (93.40–104.20) 92.81 (87.67–98.26) 92.82 (87.37–98.60) .162
Male 91.61 (84.06–99.84) 99.86 (92.32–108.03) 89.44 (80.26–99.67) 89.69 (68.59–117.29) .250
Female 90.20 (83.36–97.60) 97.76 (90.20–105.97) 94.06 (87.63–100.97) 93.39 (87.59–99.57) .516
Sitting systolic BP, mm Hgc All 119.25 (13.71) 122.11 (15.96) 123.82 (17.19) 119.08 (14.57) .508
Male 122.10 (14.37) 124.91 (19.03) 122.79 (15.12) 117.13 (11.65) .817
Female 117.16 (13.19) 119.93 (13.11) 124.28 (18.31) 119.41 (15.16) .458
Sitting diastolic BP, mm Hgc All 75.26 (8.23) 75.91 (10.55) 76.42 (9.77) 74.76 (9.58) .894
Male 74.74 (8.07) 75.96 (9.55) 76.18 (10.73) 73.87 (6.08) .948
Female 75.65 (8.56) 75.87 (11.49) 76.55 (9.55) 74.92 (10.14) .948
a Data presented as geometric mean (95% confidence interval) after log transformation.
b Significance of Tukey’s paired comparisons, significant at the 5% level; age, all: null vs B,  0.001; A vs B, 0.018; age, female: null vs B, 0.002; A
vs B, 0.036; height, all: null vs B, 0.018; height, female: null vs B, 0.029, A vs B, 0.021, B vs C, 0.001.
c Data presented as mean (SD).
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Fludrocortisone was used more frequently and in
higher doses in patients with the more severe genotypes.
However, due to the small sample size and large number
of comparisons being made, there was insufficient statis-
tical power to detect the pairs of groups between which
significant differences occurred (Table 3). Only 8%of pa-
tients with null mutations had plasma renin levels in the
upper reference range, with 79% of patients having renin
levels above the reference range indicative of underre-
placement. In addition, 26.7% of patients in group A had
a renin in the upper reference range, whereas half of the
patients in groupBwere found in the reference range (Sup-
plemental Table 2). Overtreatment, defined by renin con-
centrations either in the lower reference range or sup-
pressed, was only rarely observed throughout mutation
groups.
Fertility
Menarche occurred spontaneously in more than 80%
ofwomen (94%of null, 87%of A, 82%of B, and 94%of
C). The age of menarche was not different between mu-
tation groups [null, 14.5 years (9–25 years); A, 14.4 years
(10–20 years); B, 14.2 years (9–22 years); andC, 13 years
(9–22)].
Only 29% of women reported having ever been preg-
nant. Importantly, 59% of females reported having never
attempted to become pregnant. A clear difference was
found between patients with more severe CAH (groups
null and A) and patients with simple virilizing and non-
classic CAH (groups B and C). Approximately 80% of
women in mutation groups null and A had never tried to
have children (Supplemental Table 3). In contrast, more
than half of patients in group B had tried to have children
and 36% of patients with group B mutations had been
pregnant. About 60% of females with group Cmutations
had tried to be, and about half of all patients had been,
pregnant in this group. There was a clear age dependency.
Most women younger than 30 years had never tried to get
pregnant, whereas a significantly higher proportion of
olderwomenwhen tryingachievedbyahigher success rate
of pregnancies (Supplemental Table 3).
Mostmen in allmutations groups did not have children
(87%of null, 77%ofA, 90%ofB), and of these, 79%had
never tried to have children (73% of null, 91% of A, 78%
of B). The data set was insufficient to analyze any relation
to testicular adrenal rest tumors.
Subjective health status
We previously demonstrated significantly impaired
subjective health status in our CAH patients in compari-
son with healthy controls (10). Here we found no corre-
lation between genotype and subjective health status (Fig-
ure 2). Subjective health status was similarly impaired in
male and female patients (Figure 2C) and in patients
younger and older than 30 years.
Discussion
The CYP21A2 genotype has not been correlated previ-
ously with health outcomes in adults with CAH, except in
relation tooutcomeof surgical procedures (20) andgender
Table 2. Blood Glucose and Lipids
Gender
Mutation Group
Significance of
Mutation Group
(ANOVA)Null A B C
Glucosea All 4.60 (4.30–5.20) 4.55 (4.20–5.00) 4.50 (4.20–5.00) 4.75 (4.50–5.10) .351a
Median (quartiles) Male 4.90 (4.30–5.20) 4.60 (4.10–4.83) 4.70 (4.50–5.30) 4.80 (4.20–6.15) .476a
Female 4.50 (4.20–5.05) 4.50 (4.25–5.08) 4.30 (4.00–4.70) 4.70 (4.50–5.10) .127a
HOMA-IRb All 1.71 (1.19–2.45) 1.71 (1.35–2.16) 1.54 (1.16–2.05) 1.63 (1.26–2.10) .937
Male 1.89 (0.74–4.83) 1.71 (1.10–2.64) 1.63 (0.82–3.20) 2.89 (1.07–7.80) .801
Female 1.61 (1.12–2.31) 1.70 (1.27–2.28) 1.50 (1.09–2.05) 1.52 (1.16–2.00) .916
Cholesterol All 5.09 (1.26) 4.94 (1.21) 5.28 (1.16) 5.14 (1.16) .676
Mean (SD) Male 4.63 (0.88) 4.46 (0.90) 4.77 (0.91) 4.50 (1.47) .867
Female 5.50 (1.42) 5.28 (1.30) 5.49 (1.21) 5.27 (1.07) .876
HDLb All 1.43 (1.29–1.59) 1.53 (1.38–1.70) 1.59 (1.46–1.74) 1.54 (1.37–1.72) .532
Male 1.27 (1.08–1.49) 1.32 (1.16–1.51) 1.50 (1.21–1.86) 1.22 (0.97–1.54) .401
Female 1.58 (1.40–1.79) 1.72 (1.48–2.01) 1.63 (1.48–1.79) 1.61 (1.42–1.83) .792
LDLb All 2.87 (2.55–3.23) 2.73 (2.46–3.02) 2.96 (2.61–3.36) 2.96 (2.66–3.29) .663
Male 2.64 (2.17–3.22) 2.47 (2.09–2.91) 2.86 (2.50–3.26) 2.70 (1.25–5.84) .740
Female 3.09 (2.65–3.60) 2.96 (2.59–3.38) 3.00 (2.51–3.59) 3.01 (2.73–3.31) .981
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein. Analyses performed using 1-way ANOVA/Tukey’s paired comparisons
unless stated otherwise.
a Kruskall-Wallis test.
b Data presented as geometric mean (95% confidence interval) after log transformation.
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typical behavior (21). In children, there is a correlation
between genotype and renal salt loss (5) and impairment
of adrenomedullary function (6). The correlation between
virilization of the external genitalia in 46,XX individuals
and the CYP21A2 genotype has been variably reported,
with more severe CYP21A2 gene mutations tending to be
associated withmore severe virilization (14–16). Here we
investigated whether outcome measures in adults with
CAH related to the severity of the genotype.
Our CAH patient cohort is genetically representative
because we found the same distribution pattern of geno-
types previously described in studies analyzing the spec-
trum of CYP21A2 mutations in CAH. We, like others,
observed a reduced number of men, in particular those
with a milder genotype (16, 22, 23).
Weobserved that higher glucocorticoid doses tended to
be used in patientswithmore severemutations,whichwas
significantly different only in patients on hydrocortisone
replacement. The lack of statistical significancemightwell
be caused by the small sample size and heterogeneity of
glucocorticoid use, which included hydrocortisone, pred-
nisolone, and dexamethasone. However, the possibility
remains that either substantially different glucocorticoid
doses arenot required inpatientswith contrasting genotypes
or that the treatmentmightnotbewell adjusted to individual
requirements. In all mutation groups, only a low percentage
ofpatientshadparametersofhormonalcontrol inthedesired
target ranges (Supplemental Figure 1).
It seems that in general, patientswere often treatedwith
insufficient doses of mineralocorticoids. Importantly, pa-
tients with all disease severities may benefit from renin
measurement to assess whether they benefit from tailored
mineralocorticoid replacement. This is supported by our
findings in a few patients withinmutation groupC, which
is normally associated with nonclassic CAH. However,
several patients had increased renin levels at least 1-fold
above the normal range and were not on fludrocortisone
(Supplemental Table 2).
The strong correlation between renal salt loss pheno-
type and genotype in children (5) is reflected in our find-
ings that use of fludrocortisone and fludrocortisone dose
correlated with the underlying genotype (Supplemental
Table 2). The use of mineralocorticoids in patients with
mutation group C can be explained by the fact that even
some patient with nonclassic CAH may have subclinical
signs of salt loss (24). Thus, the overall correlation be-
tween genotype and salt loss in adults with CAH seems to
be similar to children, in whom a higher degree of sub-
clinical and clinical salt loss is observed in individualswith
the more severe genotype.
Variable outcomes have been described for most cardio-
vascular and metabolic parameters in adult patients with
CAH. Higher prevalence of obesity and lower levels of in-
sulin sensitivity in comparison with the general popu-
lation are commonly reported (7–9). Our previous re-
port on the UK CaHASE cohort illustrated suboptimal
Table 3. Glucocorticoid and Mineralocorticoid Treatment
Mutation Group
Significance
of Mutation
Group
(ANOVA)
Significance of Tukey’s Paired Comparisons
Null
vs
A
Null
vs
B
Null
vs
C
A
vs
B
A
vs
C
B
vs
CNull A B C
Hydrocortisone only
n (%) 10 (29.4%) 10 (23.8%) 9 (25.0%) 7 (20.6%) .864
Median dose (range), mg/d 30 (15–30) 25 (15–30) 30 (20–33) 20 (10–35) .021a .178 1.000 .023a 1.000 1.000 .343
Median dose per BSA
(range), mg/m2 · d
17.3 (8.1–30.8) 14.3 (7.9–16.8) 15.7 (10.7–20.3) 11.1 (4.5–20.8) .043a .321 1.000 .053 1.000 1.000 .375
Prednisolone only
n (%) 12 (35.3%) 15 (35.7%) 16 (44.4%) 17 (50.0%) .529
Median dose (range), mg/d 6.8 (5–9) 7.5 (4–10) 5.5 (3–10) 5 (1–8) .124
Median dose per BSA
(range), mg/m2 · d
3.7 (2.6–4.9) 3.5 (1.9–6.0) 3.2 (1.2–4.9) 3.0 (0.4–4.5) .324
Dexamethasone only
n (%) 6 (17.6%) 11 (26.2%) 10 (27.8%) 6 (17.6%) .629
Median dose (range), mg/d 0.50 (0.25–0.75) 0.50 (0.25–0.75) 0.35 (0.25–0.75) 0.25 (0.25–0.50) .176
Median dose per BSA
(range), mg/m2  d
0.30 (0.13–0.49) 0.24 (0.11–0.47) 0.21 (0.13–0.46) 0.14 (0.11–0.25) .246
Combination of
glucocorticoids, n (%)
6 (17.6%) 6 (14.3%) 1 (2.8%) 3 (8.8%) .171
Reverse circadian
glucocorticoid
administration, n (%)
17 (50.0%) 19 (45.2%) 17 (47.2%) 14 (41.2%) .914
Fludrocortisone
n (%) 32 (94.1%) 33 (78.6%) 14 (38.9%) 10 (29.4%) .001a .098 .001b .001b .001b .001b .457
Median dose (range), g/d 163 (100–500) 100 (50–200) 100 (50–200) 100 (50–500) .015a .134 .044a .155 1.000 1.000 1.000
Median dose per BSA
(range), g/m2  d
94 (51–231) 64 (27–134) 63 (30–121) 57 (27–219) .016a .058 .270 .074 1.000 1.000 1.000
a Significant at the 5% level.
b Significant at the Bonferroni-adjusted level of 1.67%.
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outcome and several health problems in
adults with CAH (10). However, we did
not find any relation between the under-
lying genotype and the metabolic outcome
in our patient cohort. This may well be ex-
plained, as outlined above, by a significant
proportion of patients receiving subopti-
mal management with glucocorticoids and
mineralocorticoids.
The age of menarche did not differ be-
tweenmutation groups, suggesting a sim-
ilar course of pubertal development in fe-
males. Most women with null and A
mutations in our study had never tried to
have children, which is a similar finding
to reports from Sweden (25). In contrast
to the Swedish study, we observed 1 pa-
tient with null mutations, who had 1
child. An increasing number of children
were born in patients with less severe ge-
notypes and females with milder geno-
types had tried for fertility more com-
monly (Supplemental Table 3). Using our
data set, we are able to report only on
fertility, but importantly, somerecentstud-
ies established almost normal fecundity in
women with CAH who wish to have chil-
dren (25, 26). We did not assess whether
ovulation frequency differed between pa-
tients with different genotypes. However,
factors other than hormonal control may
wellplayanimportantrole indecreasedfer-
tility in women with CAH (27). Unfortu-
nately, we did not explore sexual orienta-
tion or behavior in our patients, which
wouldhaveprovided insights into theeffect
of theunderlyinggenotypeonpotential dif-
ferences in cerebralmasculinization caused
by androgen effects on the female brain.
Others have described higher rates of ho-
mosexual and bisexual orientation in
women with CAH with increasing fre-
quency in those with severe underlying ge-
notypes (21).
Patients from all mutation groups
showed impaired subjective heath status
compared with normal controls for most
items. However, outcome between pa-
tients from different mutation groups did
not differ, and subjective health status
was similarly impaired when comparing
men and women and patients younger
Figure 2. Subjective health status according to SF-36 dimension scores for different
mutation groups (panel A): null [n  27; 13 females (f), 14 males (m)]; A (n  35; 20 f,
15 m); B (n  34; 22 f, 12 m); C (n  27; 25 f, 2 m). Panels B and C depict the same
analysis for males (B) and females (C) in a separate fashion. Results for the males in
mutation group C are not shown due to the small sample size (n  5). #, Significant
difference (P  .05) between patients and normal controls; *, difference between mutation
groups at a significance level of P  .05. SF-36 dimensions: BP, bodily pain; GH, general
health; MH, mental health; PF, physical functioning; RE, role limitations due to emotional
problems; RP, role limitations due to physical problems; SF, social functioning; VT, vitality.
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and older than 30 years of age. Comparing the different
disease severities suggests that impaired subjective health
status is caused by exogenous factors such as treatment or
noncompliance rather than by predetermined genetic fac-
tors. Chronic conditions are generally associatedwith sev-
eral difficulties potentially affecting QOL. Impaired sub-
jectivehealth statushasbeendescribed inourUKCaHASE
cohort (10). This impairment was similar to if not greater
than previously observed in patients with adrenal insuf-
ficiency on current standard replacement therapy (28).
The situation inCAHappears tobemore complexbecause
CAH features not only adrenal insufficiency but also the
additional problem of androgen excess. It is, however,
unclearwhy different studies on subjective health status in
CAHhave led to variable results. Interestingly, most stud-
ies applying the SF-36 showed an impaired subjective
health status (10, 29, 30). However, adults with CAH in
the multicenter study from the United Kingdom had a
worse subjective health status than controls and patients
with adrenal insufficiency (10), whereas a study including
2 specialized centers fromGermany showed onlymild im-
pairment compared with control and better QOL than
patients with adrenal insufficiency (30). Other studies in-
cluding adult CAHpatients did find normalQOL (21, 31)
or even better QOL in CAH patients compared with nor-
mal controls (32).Differences inhealth careprovisionmay
account for such differences, but clear evidence for such
assumptions is lacking. In a recent paper on an American
cohort of CAH patients, similar findings to ours were de-
scribed, withmost patients showing suboptimal biochem-
ical control of CAH (33). In conclusion, most current
health problems in adult CAH patients with 21OHD un-
dermedical follow-up do not correlatewith the severity of
the underlying genetic CYP21A2 genotype. This was ob-
served at an equal level in both sexes and all mutation
severity groups. The only exemption is men with nonclas-
sic CAH,whowere underrepresented in the current study.
The most likely common nongenetic influences on health
in different patients are the prescribed steroid hormone
replacement regimen and general health care provision.
Thus, the future improvement of care provision requires
improved individualized treatment strategies tailored to
the needs of individual patients. It is possible that differ-
ences between different CYP21A2 mutation groups will
be unmasked consequent to future improvements of
health care provision for adult patients with CAH.
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